Close
Smartlab Europe
Inizio Ignite

Ranbaxy Honored With Nabia Award For Excellence in New Jersey Business Expansion

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...
- Advertisement -
Smart Lab Europe

Ranbaxy Inc., a research-based pharmaceutical company that manufactures generic product formulations, OTC and branded drug products, has been honored with the New Jersey Business Industry Association’s (NJBIA) Award for Excellence in Business Expansion and Economic Contribution to the State. 

The NJBIA award acknowledges Ranbaxy’s commitment and contribution to the State,  providing jobs for more than 700 New Jerseyans and with recent investments in its state-of-the-art manufacturing facilities in New Brunswick. NJBIA President Philip Kirschnerwill honor Ranbaxy and other recipients at an awards dinner on October 18, 2011 in Edison, NJ.

Ranbaxy entered the U.S. market in 1994 with a sales office in Raleigh, North Carolina.  It acquired Ohm Laboratories of North Brunswick, NJ, its first U.S. manufacturing facility in 1995 and subsequently relocated its North American headquarters to Princeton, NJ. Ohm Laboratories produces quality and affordable generic prescription product formulations, as well as OTC medications.

Smart Lab Europe

Latest stories

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...

FDA Approves Monthly Rybrevant Faspro for EGFR-Mutated NSCLC

Johnson & Johnson (J&J) has obtained approval from the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »